Clinical Trials Logo

Clinical Trial Summary

This study monitors the efficacy and safety of Golimumab in maintaining deep remission and quality of life in Ulcerative Colitis patients in deep prolonged remission with Infliximab. Patients will be followed up for one year and they will be assessed with biochemical tests (C-Reactive Protein , Full Blood Count , Faecal Calprotectin),endoscopic evaluation (MAYO Score) and finally histologically.


Clinical Trial Description

Ulcerative colitis (UC) is a chronic idiopathic relapsing-remitting or continuously active inflammatory bowel disease (IBD) which almost exclusively affects the colonic mucosa. Acute severe flares of UC may lead onto potential lethal complications, such as massive haemorrhage, toxic megacolon, peritonitis, and colectomy whereas chronic active disease may lead to functional failure of the large bowel, dysplasia and colorectal cancer. Traditional therapeutic targets, such as normalization of stools and absence of rectal bleeding, are no longer considered sufficient to prevent the aforementioned long term sequelae of uncontrolled colonic inflammation. Thus, new therapeutic targets are emerging which aim at achieving optimal long-term outcomes of UC. Along this line, therapy is moving from mere control of symptoms towards a more global control of inflammation by achieving and maintaining long-term complete clinical remission (relief of abdominal pain, normalization of stools, and cessation of rectal bleeding), normalization of serologic (white blood cells and C-Reacting Protein) and faecal markers of inflammation (calprotectin), and endoscopic (normal looking mucosa) and histologic remission (absence of acute and chronic inflammation on biopsies from the affected colonic areas). This composite definition of remission (namely 'complete' or 'deep' remission) consisting of appropriate patient reported outcomes (PROs) and objective markers of intestinal inflammation may be associated with improved long-term outcomes of disease, such prevention of complications, hospitalizations, and colectomy, avoidance of disability and maintenance of at least near-normal patient quality of life. This composite clinical and biological remission along with mucosal healing and histologic remission is now considered as a realistic therapeutic goal.

Patients fulfilling the inclusion criteria and willing to participate will receive golimumab therapy subcutaneously for 1 year.

Patients will be followed in the outpatient IBD Clinic at 3-month intervals as is the usual practice in our department. At each visit patients will undergo clinical evaluation using the Partial Mayo score, physical examination, monitor of body weight and body mass index, and routine laboratory tests which are included in routine clinical practice of treatment with biologic agents in IBD (FBC, Estimated Sedimentation Rate, CRP, Liver Function Tests, Urea, Creatinine, serum glucose and electrolytes, and faecal calprotectin) in order to ensure effectiveness and safety of treatment. In each visit, patients will fill questionnaires to assess quality of life, disability, work productivity, and satisfaction with therapy. The daily bowel frequency, rectal bleeding, presence and grading of abdominal pain and the overall subjective condition of patient's general health between visits will be recorded daily in pre-administered diaries.

After 1 year of golimumab administration patients will be re-evaluated by endoscopy and biopsies in order to define the percentage of patients that remain at deep remission.

For those patients presenting with a flare of disease during the 1 year follow up, treatment will be individualized depending on the severity of the flare. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02868398
Study type Observational
Source Evangelismos Hospital
Contact
Status Completed
Phase
Start date June 2016
Completion date April 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2